Jasper Therapeutics (JSPR) Free Cash Flow (2020 - 2025)

Jasper Therapeutics has reported Free Cash Flow for 6 years, with the latest figure at -$21.9 million in Q4 2025.

• On a quarterly basis, Free Cash Flow fell 3.14% year-over-year to -$21.9 million in Q4 2025; TTM through Dec 2025 was -$76.5 million, a 21.12% decrease from a year earlier, with the FY2025 full-year figure at -$76.5 million, down 21.12% from the prior year.
• Free Cash Flow was -$21.9 million for Q4 2025 at Jasper Therapeutics, down from -$17.0 million in the prior quarter.
• The five-year high for Free Cash Flow was -$6.1 million in Q2 2021, with the low at -$22.6 million in Q1 2025.
• Average Free Cash Flow over 5 years is -$13.7 million, with a median of -$13.6 million recorded in 2022.
• The largest YoY upside for Free Cash Flow was 39.22% in 2021 against a maximum downside of 3396.12% in 2021.
• Over 5 years, Free Cash Flow stood at -$15.3 million in 2021, then climbed by 16.51% to -$12.8 million in 2022, then tumbled by 36.6% to -$17.4 million in 2023, then dropped by 21.52% to -$21.2 million in 2024, then retreated by 3.14% to -$21.9 million in 2025.
• The last three Free Cash Flow figures came in at -$21.9 million (Q4 2025), -$17.0 million (Q3 2025), and -$15.1 million (Q2 2025), per Business Quant data.